Phase 2Data readout

Rapamycin/Sirolimus (LAM-001) (mTOR Inhibitor)

Bronchiolitis Obliterans Syndrome

QNCXQuince Therapeutics

Expected catalystMarch 31, 2027Company guidance: Mar 31, 2027

Catalyst overview

Event details

Drug or asset: Rapamycin/Sirolimus (LAM-001) (mTOR Inhibitor)
Development stage: Phase 2
Event type: Data readout
Indication: Bronchiolitis Obliterans Syndrome

Research summary

What is being tracked?

This catalyst tracks a Phase 2 data readout for Rapamycin/Sirolimus (LAM-001) (mTOR Inhibitor) in Bronchiolitis Obliterans Syndrome. The expected timing is based on the latest available company guidance and may change.

Development notes

05/18/26:- Phase 2 BOS study ongoing. Data expected Q1 2027. 08/14/26:- Phase 2 BOS trial is fully enrolled. Data is expected in Q1 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

Phase 2Data readout

Rapamycin/Sirolimus (LAM-001) (mTOR Inhibitor)

Bronchiolitis Obliterans Syndrome

QNCXQuince Therapeutics

Expected catalystMarch 31, 2027Company guidance: Mar 31, 2027

Catalyst overview

Event details

Drug or asset: Rapamycin/Sirolimus (LAM-001) (mTOR Inhibitor)
Development stage: Phase 2
Event type: Data readout
Indication: Bronchiolitis Obliterans Syndrome

Research summary

What is being tracked?

Development notes

05/18/26:- Phase 2 BOS study ongoing. Data expected Q1 2027. 08/14/26:- Phase 2 BOS trial is fully enrolled. Data is expected in Q1 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

Rapamycin/Sirolimus (LAM-001) (mTOR Inhibitor)

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs

Sirolimus/Rapamycin (LAM-001) (mTOR Inhibitor)